Maria D Mjaavatten1, Helga Radner2, Kazuki Yoshida2, Nancy A Shadick2, Michelle L Frits2, Christine K Iannaccone2, Tore K Kvien2, Michael E Weinblatt2, Daniel H Solomon2. 1. From the Division of Rheumatology, Immunology and Allergy, and the Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria; Department of Rheumatology, Kameda Medical Center, Kamogawa, Chiba Prefecture, Japan.M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna; K. Yoshida, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and Department of Rheumatology, Kameda Medical Center; N.A. Shadick, MD, MPH; M.L. Frits, BA; C.K. Iannaccone, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital; T.K. Kvien, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; M.E. Weinblatt, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital; D.H. Solomon, MD, MPH, Division of Rheumatology, and Immunology and Allergy, and Division of Pharmacoepidemiology, Brigham and Women's Hospital. maria_mjaavatten@hotmail.com. 2. From the Division of Rheumatology, Immunology and Allergy, and the Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria; Department of Rheumatology, Kameda Medical Center, Kamogawa, Chiba Prefecture, Japan.M.D. Mjaavatten, MD, PhD, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and Department of Rheumatology, Diakonhjemmet Hospital; H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna; K. Yoshida, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and Department of Rheumatology, Kameda Medical Center; N.A. Shadick, MD, MPH; M.L. Frits, BA; C.K. Iannaccone, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital; T.K. Kvien, MD, PhD, Department of Rheumatology, Diakonhjemmet Hospital; M.E. Weinblatt, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital; D.H. Solomon, MD, MPH, Division of Rheumatology, and Immunology and Allergy, and Division of Pharmacoepidemiology, Brigham and Women's Hospital.
Abstract
OBJECTIVE: Current recommendations advocate treatment with disease-modifying antirheumatic drugs (DMARD) in all patients with active rheumatoid arthritis (RA). We investigated the frequency of and reasons for inconsistent DMARD use among patients in a clinical rheumatology cohort. METHODS: Patients in the Brigham Rheumatoid Arthritis Sequential Study were studied for DMARD use (any or none) at each semiannual study timepoint during the first 2 study years. Inconsistent use was defined as DMARD use at ≤ 40% of study timepoints. Characteristics were compared between inconsistent and consistent users (> 40%), and factors associated with inconsistent DMARD use were determined through multivariate logistic regression. A medical record review was performed to determine the reasons for inconsistent use. RESULTS: Of 848 patients with ≥ 4 out of 5 visits recorded, 55 (6.5%) were inconsistent DMARD users. Higher age, longer disease duration, and rheumatoid factor negativity were statistically significant correlates of inconsistent use in the multivariate analyses. The primary reasons for inconsistent use identified through chart review, allowing for up to 2 co-primary reasons, were inactive disease (n = 28, 50.9%), intolerance to DMARD (n = 18, 32.7%), patient preference (n = 7, 12.7%), comorbidity (n = 6, 10.9%), DMARD not being effective (n = 3, 5.5%), and pregnancy (n = 3, 5.5%). During subsequent followup, 14/45 (31.1%) inconsistent users with sufficient data became consistent users of DMARD. CONCLUSION: A small proportion of patients with RA in a clinical rheumatology cohort were inconsistent DMARD users during the first 2 years of followup. While various patient factors correlate with inconsistent use, many patients re-start DMARD and become consistent users over time.
OBJECTIVE: Current recommendations advocate treatment with disease-modifying antirheumatic drugs (DMARD) in all patients with active rheumatoid arthritis (RA). We investigated the frequency of and reasons for inconsistent DMARD use among patients in a clinical rheumatology cohort. METHODS:Patients in the Brigham Rheumatoid Arthritis Sequential Study were studied for DMARD use (any or none) at each semiannual study timepoint during the first 2 study years. Inconsistent use was defined as DMARD use at ≤ 40% of study timepoints. Characteristics were compared between inconsistent and consistent users (> 40%), and factors associated with inconsistent DMARD use were determined through multivariate logistic regression. A medical record review was performed to determine the reasons for inconsistent use. RESULTS: Of 848 patients with ≥ 4 out of 5 visits recorded, 55 (6.5%) were inconsistent DMARD users. Higher age, longer disease duration, and rheumatoid factor negativity were statistically significant correlates of inconsistent use in the multivariate analyses. The primary reasons for inconsistent use identified through chart review, allowing for up to 2 co-primary reasons, were inactive disease (n = 28, 50.9%), intolerance to DMARD (n = 18, 32.7%), patient preference (n = 7, 12.7%), comorbidity (n = 6, 10.9%), DMARD not being effective (n = 3, 5.5%), and pregnancy (n = 3, 5.5%). During subsequent followup, 14/45 (31.1%) inconsistent users with sufficient data became consistent users of DMARD. CONCLUSION: A small proportion of patients with RA in a clinical rheumatology cohort were inconsistent DMARD users during the first 2 years of followup. While various patient factors correlate with inconsistent use, many patients re-start DMARD and become consistent users over time.
Entities:
Keywords:
DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; DRUG ADHERENCE; LONGITUDINAL STUDIES; RHEUMATOID ARTHRITIS
Authors: F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra Journal: Arthritis Rheum Date: 1988-03
Authors: Siri Lillegraven; Nina Paynter; Femke H M Prince; Nancy A Shadick; Espen A Haavardsholm; Michelle L Frits; Christine K Iannaccone; Tore K Kvien; Michael E Weinblatt; Daniel H Solomon Journal: Arthritis Care Res (Hoboken) Date: 2013-04 Impact factor: 4.794
Authors: Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maya Buch; Gerd Burmester; Maxime Dougados; Paul Emery; Cécile Gaujoux-Viala; Laure Gossec; Jackie Nam; Sofia Ramiro; Kevin Winthrop; Maarten de Wit; Daniel Aletaha; Neil Betteridge; Johannes W J Bijlsma; Maarten Boers; Frank Buttgereit; Bernard Combe; Maurizio Cutolo; Nemanja Damjanov; Johanna M W Hazes; Marios Kouloumas; Tore K Kvien; Xavier Mariette; Karel Pavelka; Piet L C M van Riel; Andrea Rubbert-Roth; Marieke Scholte-Voshaar; David L Scott; Tuulikki Sokka-Isler; John B Wong; Désirée van der Heijde Journal: Ann Rheum Dis Date: 2013-10-25 Impact factor: 19.103
Authors: Anthony M Louder; Amitabh Singh; Kim Saverno; Joseph C Cappelleri; Aaron J Aten; Andrew S Koenig; Margaret K Pasquale Journal: Am Health Drug Benefits Date: 2016-04
Authors: Cynthia S Crowson; Silvia Rollefstad; George D Kitas; Piet L C M van Riel; Sherine E Gabriel; Anne Grete Semb Journal: PLoS One Date: 2017-03-23 Impact factor: 3.240
Authors: Annelieke Pasma; Charlotte Schenk; Reinier Timman; Adriaan van 't Spijker; Cathelijne Appels; Willemijn H van der Laan; Bart van den Bemt; Robert Goekoop; Johanna M W Hazes; Jan J V Busschbach Journal: PLoS One Date: 2017-02-02 Impact factor: 3.240